Pre-treatment with sumatriptan for cilostazol induced headache in healthy volunteers
Katrine Falkenberg, Jes Olesen, Katrine Falkenberg, Jes Olesen
Abstract
Background: Previous studies indicate that sumatriptan is not effective when second messenger levels are high as after cilostazol provocation. Therefore, we have conducted the present study, where sumatriptan is administrated as pretreatment before cAMP increases due to cilostazol intake. Our hypothesis was that pretreatment with sumatriptan would have a significant effect against cilostazol induced headache in healthy volunteers.
Methods: In a double-blind, randomized, crossover design, 30 healthy volunteers of both sexes received cilostazol 200 mg on two separate days, each day preceded by oral sumatriptan (2 × 50 mg) or placebo. Headache response and accompanying symptoms were registered in a questionnaire by the participants themselves.
Results: Cilostazol induced a mild to moderate headache in all but 3 participants (Range 0-7 on Numerical Rating Scale). There was no significant difference in headache score 2 h (p = 0.67) or 4 h (p = 0.1) after treatment between the 2 days. Median peak headache score was 1.5 (range 0-5) on the sumatriptan day and 2 (range 0-7) on the placebo day (p = 0.26).
Conclusion: Pre-treatment with sumatriptan prevents cilostazol induced headache from developing. However, the placebo group did not develop enough headache to get statistical significant results. The cilostazol pre-treatment model is valuable for experimental headache research and perhaps for testing drugs with another mechanism of action.
Trial registration: ClinicalTrials.gov Identifier: NCT03156920 .
Keywords: Headache; Human migraine model; Migraine; Pain; Phosphodiesterase type 3.
Conflict of interest statement
Ethics approval and consent to participateThe study was approved by the Ethics Committee of Copenhagen (H-15011960). All participants received oral and written information and provided written informed consent before inclusion in the study.
Consent for publicationNot applicable.
Competing interestsThe authors declare that they have no competing interests.
Publisher’s NoteSpringer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Figures
References
- Liu Y, Shakur Y, Yoshitake M, et al. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev. 2001;19:369–386. doi: 10.1111/j.1527-3466.2001.tb00076.x.
- Guo S, Olesen J, Ashina M. Phosphodiesterase 3 inhibitor cilostazol induces migraine-like attacks via cyclic AMP increase. Brain. Epub ahead of print 26 August 2014. DOI: 10.1093/brain/awu244
- Hansen EK, Olesen J. Towards a pragmatic human migraine model for drug testing: 2. Isosorbide-5-mononitrate in healthy individuals. Cephalalgia. 2017;37:11–19. doi: 10.1177/0333102416636095.
- Hansen EK, Guo S, Ashina M, et al. Toward a pragmatic migraine model for drug testing: I. Cilostazol in healthy volunteers. Cephalalgia. 2016;36:172–178. doi: 10.1177/0333102415583986.
- Falkenberg K, Dunga BÓÁ, Guo S, et al. Cilostazol induced migraine does not respond to sumatriptan in a double blind trial. J Headache Pain. 2018;19:11. doi: 10.1186/s10194-018-0841-7.
- National Center for clinical trial registrations. Raske forsøgspersoner søges til migræneforsøg. 2017. . Accessed 28 Aug 2017.
- (IHS) HCC of the IHS The international classification of headache disorders, 3rd edition (beta version) Cephalalgia. 2013;33:629–808. doi: 10.1177/0333102413485658.
- Birk S, Kruuse C, Petersen KA, et al. The headache-inducing effect of cilostazol in human volunteers. Cephalalgia. 2006;26:1304–1309. doi: 10.1111/j.1468-2982.2006.01218.x.
Source: PubMed